Inotuzumab continues to wow against relapsed/refractory ALL

Copenhagen – The experimental antibody-drug conjugate inotuzumab ozogamicin was associated with a nearly threefold higher complete remission rate than standard intensive chemotherapy in patients with...
Source: Family Practice News - Category: Primary Care Source Type: news